Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVO
Post# of 52
(Total Views: 340)
Posted On: 05/25/2018 8:34:24 PM
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Targeting Growing CBD Pet Market with New Product Line
- Company’s new products are designed to address issues such as inflammation, joint pain, post-surgery pain and skin disorders in pets
- CBD pet market is heating up, with a growing number of cannabis companies already manufacturing products for this niche
- Pet owners spend more than $30 billion a year on supplements and other veterinary treatments, making CBD pet products a lucrative opportunity
The multiple uses of cannabidiol (CBD) for domesticated animals, especially for dogs and cats, are gaining considerable attention from both consumers and the cannabis industry as a whole, with a growing number of cannabis companies tapping into this lucrative market sector. Canadian-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) already has several CBD-based pet products in development, targeting indications such as inflammation, post-surgical pain and joint pain, as well as skin disorders.
Pivot recently announced that it was accelerating development of its CBD pet product line, which will be marketed under the name ‘Pivot Naturals For Pets’ (http://nnw.fm/ZV1gi). This product line will include capsules and sachets to deliver bio-available CBD, using Pivot’s proprietary and patented Ready-To-Infuse-Cannabis powder. In addition, the company is using its Thrudermic Transdermal Nanotechnology to develop and commercialize a series of CBD pet creams for topical application.
“With Pivot’s line of pet products, the pain-relieving effects of CBD can be delivered orally, topically or as an additive sprinkled on pet food. Pivot’s technologies are versatile and allow us to develop and commercialize products for both the human and veterinary markets,” Dr. Joseph Borovsky, Pivot’s executive vice president, product development, stated in a news release. He added that the company’s patented technologies will allow it to continue its innovation process to bring dozens of value-added derivatives to market in Canada, the United States and the European Union.
The Canadian cannabis market is yet to reach its full potential, with an exponential increase expected this year once the country fully legalizes cannabis. Legalization, in combination with a growing demand for CBD products for pets in both Canada and the U.S., is expected to make this investment avenue a very lucrative opportunity. According to the American Pet Products Association, pet owners in the U.S. spent more than $30 billion on supplements and other veterinary treatments in 2016. The U.S. pet medicine market alone is estimated at roughly $10.2 billion.
With several studies indicating that CBD interacts in a similar way in canines and felines, making it a viable option to address a wide range of issues such as anxiety, allergies, lack of appetite, arthritis or skin problems (http://nnw.fm/4oBjx), Pivot can successfully leverage its experience and innovative manufacturing technologies to take a leading position in the CBD pet market.
The company is already well positioned to develop industry-leading, high-quality cannabinoid-based products for pharmaceutical and nutraceutical use, through proprietary drug delivery platforms via its own medical cannabis product division, Pivot Green Stream Health Solutions (“PGS”). Responsible for the research, development and commercialization of the company’s products, PGS has acquired global rights for several patented technologies, including BiPhasix™ transdermal drug delivery, Solmic oral solubilization, Thrudermic Transdermal Nanotechnology and Ready-to-Infuse-Cannabis powder-to-oil technology. These technologies are at the foundation of the company’s pipeline of pharmaceutical products, which target different ailments and conditions ranging from cancer supportive care to glaucoma, women’s sexual desire disorder, dermatological conditions, opioid withdrawal, pain and inflammation, and many others.
For more information, visit the company’s website at www.PivotPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Company’s new products are designed to address issues such as inflammation, joint pain, post-surgery pain and skin disorders in pets
- CBD pet market is heating up, with a growing number of cannabis companies already manufacturing products for this niche
- Pet owners spend more than $30 billion a year on supplements and other veterinary treatments, making CBD pet products a lucrative opportunity
The multiple uses of cannabidiol (CBD) for domesticated animals, especially for dogs and cats, are gaining considerable attention from both consumers and the cannabis industry as a whole, with a growing number of cannabis companies tapping into this lucrative market sector. Canadian-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) already has several CBD-based pet products in development, targeting indications such as inflammation, post-surgical pain and joint pain, as well as skin disorders.
Pivot recently announced that it was accelerating development of its CBD pet product line, which will be marketed under the name ‘Pivot Naturals For Pets’ (http://nnw.fm/ZV1gi). This product line will include capsules and sachets to deliver bio-available CBD, using Pivot’s proprietary and patented Ready-To-Infuse-Cannabis powder. In addition, the company is using its Thrudermic Transdermal Nanotechnology to develop and commercialize a series of CBD pet creams for topical application.
“With Pivot’s line of pet products, the pain-relieving effects of CBD can be delivered orally, topically or as an additive sprinkled on pet food. Pivot’s technologies are versatile and allow us to develop and commercialize products for both the human and veterinary markets,” Dr. Joseph Borovsky, Pivot’s executive vice president, product development, stated in a news release. He added that the company’s patented technologies will allow it to continue its innovation process to bring dozens of value-added derivatives to market in Canada, the United States and the European Union.
The Canadian cannabis market is yet to reach its full potential, with an exponential increase expected this year once the country fully legalizes cannabis. Legalization, in combination with a growing demand for CBD products for pets in both Canada and the U.S., is expected to make this investment avenue a very lucrative opportunity. According to the American Pet Products Association, pet owners in the U.S. spent more than $30 billion on supplements and other veterinary treatments in 2016. The U.S. pet medicine market alone is estimated at roughly $10.2 billion.
With several studies indicating that CBD interacts in a similar way in canines and felines, making it a viable option to address a wide range of issues such as anxiety, allergies, lack of appetite, arthritis or skin problems (http://nnw.fm/4oBjx), Pivot can successfully leverage its experience and innovative manufacturing technologies to take a leading position in the CBD pet market.
The company is already well positioned to develop industry-leading, high-quality cannabinoid-based products for pharmaceutical and nutraceutical use, through proprietary drug delivery platforms via its own medical cannabis product division, Pivot Green Stream Health Solutions (“PGS”). Responsible for the research, development and commercialization of the company’s products, PGS has acquired global rights for several patented technologies, including BiPhasix™ transdermal drug delivery, Solmic oral solubilization, Thrudermic Transdermal Nanotechnology and Ready-to-Infuse-Cannabis powder-to-oil technology. These technologies are at the foundation of the company’s pipeline of pharmaceutical products, which target different ailments and conditions ranging from cancer supportive care to glaucoma, women’s sexual desire disorder, dermatological conditions, opioid withdrawal, pain and inflammation, and many others.
For more information, visit the company’s website at www.PivotPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)